

On-line Table 1: Cardioembolism—clinical and imaging characteristics that distinguish cardioembolism (n = 65) from definite arteriopathy (n = 109)^a

Characteristic	Prevalence in Cardioembolic Cases (n = 65)		Prevalence in Arteriopathic Cases (n = 109)		Univariate Analyses			Multivariable Analysis ^b		
	No.	%	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics										
Age by category										
0–3 yr	29	(44.6)	30	(27.5)	Reference					
4–7 yr	8	(12.3)	37	(33.9)	0.22	(0.09–0.56)	.001			
8–11 yr	7	(10.8)	17	(15.6)	0.43	(0.15–1.18)	.10			
12–15 yr	11	(16.9)	14	(12.8)	0.81	(0.32–2.08)	.67			
16–18 yr	10	(15.4)	11	(10.1)	0.94	(0.35–2.55)	.90			
Stroke presentation										
Any focal signs (vs nonfocal only)	54	(83.1)	101	(92.7)	2.67	(0.96–7.42)	.059			
Focal signs										
Ataxia	4	(6.2)	24	(22.0)	0.23	(0.08–0.74)	.01			
Hemiparesis	52	(80.0)	91	(83.5)	0.91	(0.39–2.16)	.84			
Dysarthria	14	(21.5)	33	(30.3)	0.75	(0.35–1.59)	.45			
Aphasia	12	(18.5)	29	(26.6)	0.62	(0.27–1.45)	.27			
Visual field deficit	10	(15.4)	11	(10.1)	1.68	(0.66–4.30)	.28			
Nonfocal signs										
Headache	12	(18.5)	40	(36.7)	0.47	(0.22–1.03)	.06			
Nausea/vomiting	5	(7.7)	28	(25.7)	0.26	(0.09–0.72)	.009			
Decreased level of consciousness	20	(30.8)	30	(27.5)	1.37	(0.68–2.75)	.37			
Seizures at presentation	15	(23.1)	27	(24.8)	0.97	(0.47–2.00)	.93			
Vertigo	4	(6.2)	11	(10.1)	0.60	(0.18–2.01)	.41			
Diplopia	1	(1.5)	1	(0.9)	1.87	(0.11–30.6)	.66			
Risk factors or comorbidities (not mutually exclusive)										
Cardiac disease	65	(100.0)	6	(5.5)			<.0001 ^c	101.6	(17.3–596)	<.0001
CHD only	42	(64.6)	6	(5.5)						
AHD only	19	(29.2)	0							
Both CHD and AHD	4	(6.2)	0							
Other chronic disorders										
Sickle cell anemia	0		9	(8.3)	–		.03 ^c			
Indwelling catheter	5	(7.7)	1	(0.9)	9.00	(1.03–78.8)	.05			
Acute systemic illness										
Meningitis	0		11	(10.1)	–		.008 ^c			
Vascular imaging findings										
Pathologic finding										
Occlusion	31	(47.7)	67	(61.5)	0.57	(0.31–1.06)	.08			
Stenosis	7	(10.8)	74	(67.9)	0.06	(0.02–0.14)	<.0001 ^b	0.07	(0.02–0.28)	<.0001
Irregularity	6	(9.2)	57	(52.3)	0.09	(0.04–0.23)	<.0001 ^b	0.09	(0.02–0.34)	<.0001
Banding	0		7	(6.4)	–		.05 ^c			
Pathologically affected vessels										
Arterial segments affected										
>1	24	(36.9)	94	(86.2)	Reference					
1	41	(63.1)	15	(13.8)	10.7	(5.10–22.5)	<.0001			
Vascular territories affected										
>1	7	(10.8)	49	(45.0)	Reference					
1	58	(89.2)	60	(55.0)	6.77	(2.83–16.2)	<.0001 ^b	6.63	(1.40–31.3)	.02
Side affected										
Bilateral	6	(9.2)	49	(45.0)	Reference					
Unilateral	59	(90.8)	60	(55.0)	4.08	(1.57–10.6)	.004			
Segment affected										
Supraclinoid ICA	12	(18.5)	68	(62.4)	0.14	(0.07–0.29)	<.0001			
Proximal MCA (M1)	25	(38.5)	86	(78.9)	0.17	(0.08–0.33)	<.0001			
Vertebrobasilar artery	7	(10.8)	30	(27.5)	0.32	(0.13–0.77)	.01			
Cervical arteries	9	(13.8)	27	(24.8)	0.49	(0.21–1.12)	.09			

Note:—CHD indicates congenital heart disease; AHD, acquired heart disease; –, cannot be calculated.

^a Full list of variables tested is shown in On-line Table 5.

^b Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

^c P value was calculated with the Fisher exact test.

On-line Table 2: Dissection—clinical and imaging characteristics that distinguish arterial dissection (n = 26), compared with all other definite arteriopathy subtypes (n = 83)^a

Characteristic	Prevalence (n = 26)		Univariate Analyses			Multivariable Analysis ^b		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Stroke presentation								
Focal signs								
Hemiparesis	17	(65.4)	0.23	(0.08–0.70)	.01			
Ataxia	10	(38.5)	2.91	(1.06–8.02)	.04			
Nonfocal signs								
Headache	15	(57.7)	3.30	(1.23–8.87)	.02			
Nausea/vomiting	13	(50.0)	4.96	(1.86–13.2)	.001			
Seizures at presentation	3	(11.5)	0.31	(0.08–1.13)	.08			
Vertigo	8	(30.8)	11.2	(2.64–47.9)	.001			
Risk factors or comorbidities (not mutually exclusive)								
Acute systemic illness								
Meningitis	0		–		.06 ^c			
Head trauma	10	(38.5)	51.3	(6.13–428.8)	<.0001 ^b	162	(10.7–3435)	<.0001
Infarct characteristics at baseline								
Location								
Vascular distribution of infarction								
Anterior circulation	11	(42.3)	0.05	(0.01–0.15)	<.0001			
ACA	2	(7.7)	0.45	(0.09–2.13)	.31			
Lenticulostriate artery	9	(34.6)	0.60	(0.24–1.49)	.27			
Superficial MCA	10	(38.5)	0.20	(0.08–0.51)	.001			
Anterior choroidal artery	1	(3.8)	0.62	(0.07–5.60)	.67			
Posterior circulation	12	(46.2)	34.7	(7–172)	<.0001			
Basilar artery	3	(11.5)	–		.01 ^c			
SCA	7	(26.9)	30.2	(3.51–260)	.002			
AICA	1	(3.8)	–		.24 ^c			
PICA	9	(34.6)	21.4	(4.25–108)	<.0001			
PCA	6	(23.1)	2.81	(0.87–9.04)	.08			
Other location	0				.34 ^c			
Vascular imaging findings								
Pathologic finding								
Occlusion	21	(80.8)	3.38	(1.16–9.82)	.03			
Stenosis	14	(53.8)	0.45	(0.18–1.11)	.08			
Irregularity	12	(46.2)	0.72	(0.30–1.75)	.47			
Ectasia or fusiform aneurysm or pseudoaneurysm	3	(11.5)	2.03	(0.45–9.17)	.36			
Intimal flap or mural hematoma	3	(11.5)	–		.01 ^c			
Pathologically affected vessels								
Vascular territories affected								
>1	4	(15.4)	Reference					
1	22	(84.6)	6.51	(2.06–20.6)	.001			
Side affected								
Bilateral	4	(15.4)	Reference					
Unilateral	22	(84.6)	6.51	(2.06–20.6)	.001			
Segment affected								
Supraclinoid ICA	9	(34.6)	0.22	(0.08–0.55)	.001			
Proximal MCA (M1)	10	(38.5)	0.06	(0.02–0.17)	<.0001			
Vertebrobasilar	16	(61.5)	7.89	(2.97–20.9)	<.0001			
Cervical arteries	18	(69.2)	18.5	(6.27–54.6)	<.0001 ^b	29.3	(5.43–159)	<.0001

Note:—ACA indicates anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery; SCA, superior cerebellar artery; AICA, anterior inferior cerebellar artery; PIC, posterior inferior cerebellary artery; –, cannot be calculated.

^a Full list of variables tested is shown in On-line Table 5.

^b Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

^c P value was calculated with the Fisher exact test.

On-line Table 3: FCA-i—clinical and imaging characteristics that distinguish FCA-i (n = 25) compared with all other definite arteriopathy subgroups (n = 84)^a

Characteristic	Prevalence (n = 25)		Univariate Analyses			Multivariable Analysis ^b		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics								
Age by category								
0–3 yr	2	(8.0)	Reference					
4–7 yr	7	(28.0)	3.27	(0.63–17.1)	.16			
8–11 yr	6	(24.0)	7.64	(1.33–43.8)	.02			
12–15 yr	8	(32.0)	18.7	(3.14–111)	.001			
16–18 yr	2	(8.0)	3.11	(0.38–25.4)	.29			
Stroke presentation								
Focal signs								
Dysarthria	13	(52.0)	3.68	(1.36–9.96)	.01 ^c	8.34	(1.50–46.3)	.02
Aphasia	8	(32.0)	4.19	(1.00–17.6)	.05			
Nonfocal signs								
Headache	16	(64.0)	3.19	(1.22–8.30)	.02			
Risk factors or comorbidities (not mutually exclusive)								
Meningitis	0		–		.07 ^b			
Head trauma	0		–		.07 ^b			
Infarct characteristics at baseline								
Location								
Vascular distribution of infarction								
Anterior circulation	25	(100.0)	–		.006 ^b			
ACA	0		–		.02 ^b			
Lenticulostriate artery	19	(76.0)	6.01	(2.16–16.7)	.001 ^c	45.6	(4.81–433)	.001
Superficial MCA	14	(56.0)	0.54	(0.22–1.35)	.19			
Anterior choroidal artery	4	(16.0)	7.81	(1.34–45.6)	.02			
Posterior circulation	0		–		.04 ^b			
Infarct side								
Unilateral	25	(100.0)			.001 ^b			
Bilateral	0							
Largest infarct volume (median) (IQR) (cm ³)	13.8	(3.3–20.1)						
Volume <25 cm ³	20	(80.0)	6.84	(2.33–20.0)	<.0001 ^c	5.48	(1.31–23.0)	.02
Vascular imaging findings								
Pathologic finding								
Occlusion	10	(40.0)	0.32	(0.13–0.79)	.01			
Stenosis	15	(60.0)	0.64	(0.25–1.61)	.34			
Irregularity	15	(60.0)	1.5	(0.61–3.72)	.38			
Banding	6	(24.0)	26.2	(2.98–230)	.003 ^c	193	(1.72–22K)	.03
Pathologically affected vessels								
Arterial segments affected								
>1	18	(72.0)	Reference					
1	7	(28.0)	3.69	(1.19–11.5)	.02 ^c	18.9	(1.49–240)	.02
Vascular territories affected								
>1	0				<.0001 ^b			
1	25	(100.0)	–					
Side affected								
Bilateral	0		–		<.0001 ^b			
Unilateral	25	(100.0)	–					
Segment affected								
Supraclinoid ICA	10	(40.0)	0.3	(0.12–0.75)	.01			
Proximal MCA (M1)	24	(96.0)	8.52	(1.09–66.7)	.04 ^a	24.2	(1.45–405)	.03
Vertebrobasilar	0		–					
Cervical arteries	1	(4.0)	0.09	(0.01–10.72)	.02			

Note:—IQR indicates interquartile range; –, cannot be calculated; K, thousands; ACA, anterior cerebral artery.

^a Full list of variables tested is shown in On-line Table 5.

^b P value was calculated with the Fisher exact test.

^c Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

On-line Table 4: Moyamoya disease—clinical and imaging characteristics that distinguish Moyamoya disease (n = 34) compared with all other definite arteriopathy subgroups (n = 75)^a

Characteristic	Prevalence (n = 34)		Univariate Analyses			Multivariable Analysis ^b		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics								
Race								
White	16	(47.1)	Reference					
Black	10	(29.4)	7.65	(2.11–27.8)	.002 ^b	43.2	(2.38–781)	.01
Indian/South Asian	2	(5.9)	0.51	(0.10–2.53)	.41			
East Asian	1	(2.9)	1.53	(0.13–18.0)	.74			
Middle Eastern	0		–					
First Nations/Aboriginal	0		–					
Mixed or other	3	(8.8)	1.53	(0.34–6.84)	.58			
Unknown	2	(5.9)	6.13	(0.52–72.1)	.15			
Stroke presentation								
Nonfocal signs								
Headache	3	(8.8)	0.08	(0.02–0.30)	<.0001			
Decreased level of consciousness	4	(11.8)	0.27	(0.09–0.87)	.03 ^a	0.01	(0.0009–0.19)	.002
Vertigo	0		–		.01 ^c			
Risk factors or comorbidities (not mutually exclusive)								
Other chronic disorders								
Sickle cell anemia	9	(26.5)	–		<.0001 ^c			
Down syndrome	6	(17.6)	15.9	(1.83–138)	.01 ^b	2099	(134–328K)	.003
Acute systemic illness								
Infection reported in prior 7 days	8	(23.5)	3.54	(1.12–11.2)	.03 ^b	30.0	(1.58–569)	.02
Meningitis	0		–		.02 ^c			
Dehydration	4	(11.8)	9.87	(1.06–91.9)	.04			
Infarct characteristics at baseline								
Location								
Vascular distribution of infarction								
Anterior circulation								
ACA	5	(14.7)	1.12	(0.35–3.57)	.85			
Lenticulostriate artery	8	(23.5)	0.27	(0.11–0.67)	.005			
Superficial MCA	30	(88.2)	5.58	(1.79–17.4)	.003			
Anterior choroidal artery	0		–		.17 ^c			
Posterior circulation								
Basilar artery	0		–		.005 ^c			
SCA	0		–		.55 ^c			
SCA	0		–		.06 ^c			
AICA	0		–		1.00 ^c			
PICA	0		–		.02 ^c			
PCA	0		–		.005 ^c			
Other location	4	(11.8)	9.87	(1.06–91.9)	.04			
Vascular imaging findings								
Pathologic finding								
Occlusion								
Vascular territories affected								
>1	25	(73.5)	2.18	(0.90–5.30)	.09			
1	3	(8.8)	Reference			325.0	(19.1–5522)	<.0001
Segment affected								
Supraclinoid ICA	32	(94.1)	17.3	(3.87–77.6)	<.0001 ^b	61.0	(2.32–1602)	.01
Proximal MCA (M1)	32	(94.1)	6.22	(1.37–28.3)	.02			
Vertebrobasilar	7	(20.6)	0.59	(0.22–1.54)	.28			
Cervical arteries	6	(17.6)	0.55	(0.20–1.52)	.25			

Note:— indicates that cannot be calculated; K, thousands; ACA, anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery.

^a Full list of variables tested is shown in On-line Table 5.

^b Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

^c P value was calculated with the Fisher exact test.

On-line Table 5: Cardioembolism—prevalence, univariate and multivariable analyses of demographics, and clinical and imaging characteristics for patients with cardioembolism (n = 65) versus those with definite arteriopathy (n = 109)

Characteristic	Prevalence in Cardioembolic Cases (n = 65)		Prevalence in Arteriopathic Cases (n = 109)		Univariate Analyses			Multivariable Analysis ^b		
	No.	%	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics										
Age by category										
0–3 yr	29	(44.6)	30	(27.5)	Reference					
4–7 yr	8	(12.3)	37	(33.9)	0.22	(0.09–0.56)	.001			
8–11 yr	7	(10.8)	17	(15.6)	0.43	(0.15–1.18)	.10			
12–15 yr	11	(16.9)	14	(12.8)	0.81	(0.32–2.08)	.67			
16–18 yr	10	(15.4)	11	(10.1)	0.94	(0.35–2.55)	.90			
Male sex	34	(52.3)	(58.0)	(53.2)	0.96	(0.52–1.78)	.91			
Race										
White	45	(69.2)	65	(59.6)	Reference					
Black	4	(6.2)	14	(12.8)	0.41	(0.13–1.34)	.4			
Indian/South Asian	4	(6.2)	14	(12.8)	0.41	(0.13–1.34)	.14			
East Asian	2	(3.1)	3	(2.8)	0.96	(0.15–6.00)	.97			
Middle Eastern	1	(1.5)	0	0	–					
First Nations/Aboriginal	1	(1.5)	1	(0.9)	1.44	(0.09–23.7)	.80			
Mixed or other	8	(12.3)	9	(8.3)	1.28	(0.46–3.58)	.63			
Unknown	0		3	(2.8)	–					
Stroke presentation										
Any focal signs (vs nonfocal only)	54	(83.1)	101	(92.7)	2.67	(0.96–7.42)	.059			
Focal signs										
Hemiparesis	52	(80.0)	91	(83.5)	0.91	(0.39–2.16)	.84			
Dysarthria	14	(21.5)	33	(30.3)	0.75	(0.35–1.59)	.45			
Aphasia	12	(18.5)	29	(26.6)	0.62	(0.27–1.45)	.27			
Ataxia	4	(6.2)	24	(22.0)	0.23	(0.08–0.74)	.01			
Visual field deficit	10	(15.4)	11	(10.1)	1.68	(0.66–4.30)	.28			
Nonfocal signs										
Headache	12	(18.5)	40	(36.7)	0.47	(0.22–1.03)	.06			
Decreased level of consciousness	20	(30.8)	30	(27.5)	1.37	(0.68–2.75)	.37			
Nausea/vomiting	5	(7.7)	28	(25.7)	0.26	(0.09–0.72)	.009			
Seizures at presentation	15	(23.1)	27	(24.8)	0.97	(0.47–2.00)	.93			
Vertigo	4	(6.2)	11	(10.1)	0.60	(0.18–2.01)	.41			
Diplopia	1	(1.5)	1	(0.9)	1.87	(0.11–30.6)	.66			
Risk factors or comorbidities (not mutually exclusive)										
Cardiac disease	65	(100.0)	6	(5.5)			<.0001 ^a			
CHD only	42	(64.6)	6	(5.5)				101.6	(17.3–596)	<.0001
AHD only	19	(29.2)	0							
Both CHD and AHD	4	(6.2)	0							
Other chronic disorders										
Sickle cell anemia	0		9	(8.3)	–					.03 ^a
Down syndrome	1	(1.5)	7	(6.4)	0.23	(0.03–1.89)	.17			
Other genetic syndrome	5	(7.7)	4	(3.7)	2.19	(0.57–8.46)	.26			
Migraine	1	(1.5)	3	(2.8)	0.55	(0.06–5.42)	.61			
Prothrombotic state	4	(6.2)	2	(1.8)	3.51	(0.62–19.7)	.15			
Indwelling catheter	5	(7.7)	1	(0.9)	9.00	(1.03–78.8)	.05			
Iron deficiency anemia	1	(1.5)	4	(3.7)	0.41	(0.04–3.75)	.43			
Connective tissue disease	0		1	(0.9)	–					1.00 ^a
Ventriculoperitoneal shunt	0		1	(0.9)	–					1.00 ^a
Acute systemic illness										
Infection reported in prior week	14	(21.5)	14	(12.8)	1.86	(0.82–4.21)	.14			
Systemic sepsis or bacteremia	5	(7.7)	6	(5.5)	1.43	(0.42–4.89)	.57			
Meningitis	0		11	(10.1)	–					.008 ^a
Dehydration	6	(9.2)	5	(4.6)	2.12	(0.62–7.22)	.23			
Head trauma	3	(4.6)	11	(10.1)	0.43	(0.12–1.61)	.21			
Infarct characteristics at baseline										
Location										
Vascular distribution of infarction										
Anterior circulation										
ACA	54	(83.1)	89	(81.7)	1.10	(0.49–2.48)	.81			
Lenticulostriate artery	7	(10.8)	15	(13.8)	0.76	(0.29–1.97)	.57			
Superficial MCA	27	(41.5)	48	(44.0)	0.90	(0.48–1.68)	.75			
Anterior choroidal artery	47	(72.3)	73	(67.0)	1.29	(0.66–2.53)	.46			
Posterior circulation	1	(1.5)	6	(5.5)	0.27	(0.03–2.28)	.23			
Basilar artery	19	(29.2)	14	(12.8)	1.39	(0.69–2.78)	.36			
Basilar artery	1	(1.5)	3	(2.8)	0.55	(0.06–5.42)	.61			
SCA	1	(1.5)	8	(7.3)	0.20	(0.02–1.61)	.13			
AICA	0		1	(0.9)	–					1.00 ^a
PICA	7	(10.8)	11	(10.1)	1.08	(0.39–2.93)	.89			
PCA	13	(20.0)	14	(12.8)	1.70	(0.74–3.88)	.21			
Other location	2	(3.1)	5	(4.6)	0.66	(0.12–3.51)	.63			
Infarct side										
Unilateral	43	(66.2)	83	(76.1)	Reference					
Bilateral	22	(33.8)	26	(23.9)	1.63	(0.83–3.21)	.16			

Continued on next page

On-line Table 5: Continued

Characteristic	Prevalence in Cardioembolic Cases (n = 65)		Prevalence in Arteriopathic Cases (n = 109)		Univariate Analyses			Multivariable Analysis ^b		
	No.	%	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Largest infarct volume (median) (IQR) (cm ³)	18.5	(4.21–58.8)	28	(6.5–88.9)						
Volume <25 cm ³	38	(58.5)	58	(53.2)	1.60	(0.86–2.98)	.14			
Vascular imaging findings										
Pathologic finding										
Occlusion	31	(47.7)	67	(61.5)	0.57	(0.31–1.06)	.08			
Stenosis	7	(10.8)	74	(67.9)	0.06	(0.02–0.14)	<.0001 ^b	0.07	(0.02–0.28)	<.0001
Irregularity	6	(9.2)	57	(52.3)	0.09	(0.04–0.23)	<.0001 ^b	0.09	(0.02–0.34)	<.0001
Ectasia or fusiform aneurysm or pseudoaneurysm	1	(1.5)	8	(7.3)	0.20	(0.02–1.61)	.13			
Banding	0		7	(6.4)	–		.05 ^a			
Intimal flap or mural hematoma	0		3	(2.8)	–		.29 ^a			
Pathologically affected vessels										
Arterial segments affected										
>1	24	(36.9)	94	(86.2)	Reference					
1	41	(63.1)	15	(13.8)	10.7	(5.10–22.5)	<.0001			
Vascular territories affected										
>1	7	(10.8)	49	(45.0)	Reference					
1	58	(89.2)	60	(55.0)	6.77	(2.83–16.2)	<.0001 ^b	6.63	(1.40–31.3)	.02
Side affected										
Bilateral	6	(9.2)	49	(45.0)	Reference					
Unilateral	59	(90.8)	60	(55.0)	4.08	(1.57–10.6)	.004			
Segment affected										
Supraclinoid ICA	12	(18.5)	68	(62.4)	0.14	(0.07–0.29)	<.0001			
Proximal MCA (M1)	25	(38.5)	86	(78.9)	0.17	(0.08–0.33)	<.0001			
Vertebrobasilar artery	7	(10.8)	30	(27.5)	0.32	(0.13–0.77)	.01			
Cervical arteries	9	(13.8)	27	(24.8)	0.49	(0.21–1.12)	.09			

Note:— – indicates that cannot be calculated; ACA, anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery; CHD, congenital heart disease; AHD, acquired heart disease; IQR, interquartile range.

^a P value was calculated with the Fisher exact test.

^b Remains significant (P < .05) in the multivariable model after stepwise regression (P < .05).

On-line Table 6: Dissection—prevalence and univariate analyses of characteristics associated with arterial dissection (n = 26) compared with all other definite arteriopathy subtypes (n = 83)

Characteristic	Prevalence (n = 26)		Univariate Analyses			Multivariable Analysis ^a		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics								
Age by category								
0–3 yr	6	(23.1)	Reference					
4–7 yr	8	(30.8)	1.10	(0.34–3.62)	.87			
8–11 yr	5	(19.2)	1.67	(0.42–6.59)	.47			
12–15 yr	3	(11.5)	1.09	(0.23–5.19)	.91			
16–18 yr	4	(15.4)	2.29	(0.50–10.4)	.29			
Male sex	16	(61.5)	1.56	(0.64–3.84)	.33			
Race								
White	19	(73.1)	Reference					
Black	0		–					
Indian/South Asian	2	(7.7)	0.40	(0.08–1.98)	.26			
East Asian	1	(3.8)	1.21	(0.10–13.2)	.88			
Middle Eastern	0		–					
First Nations/Aboriginal	0		–					
Mixed or other	4	(15.4)	1.94	(0.47–8.01)	.36			
Unknown	0		–					
Stroke presentation								
Focal signs								
Hemiparesis	17	(65.4)	0.23	(0.08–0.70)	.01			
Dysarthria	7	(26.9)	0.81	(0.29–2.24)	.68			
Aphasia	4	(15.4)	0.21	(0.09–1.13)	.08			
Ataxia	10	(38.5)	2.91	(1.06–8.02)	.04			
Visual field deficit	3	(11.5)	1.09	(0.26–4.52)	.91			
Nonfocal signs								
Headache	15	(57.7)	3.30	(1.23–8.87)	.02			
Decreased level of consciousness	9	(34.6)	1.39	(0.54–3.59)	.50			
Nausea/vomiting	13	(50.0)	4.96	(1.86–13.2)	.001			
Seizures at presentation	3	(11.5)	0.31	(0.08–1.13)	.08			
Vertigo	8	(30.8)	11.2	(2.64–47.9)	.001			
Diplopia	0		–		1.00 ^b			
Risk factors or comorbidities (not mutually exclusive)								
CHD and/or AHD	1	(3.8)	0.62	(0.07–5.60)	.67			
CHD only	1	(3.8)	0.62	(0.07–5.60)	.67			
AHD only	0		–					
Both CHD and AHD	0		–					
Other chronic disorders								
Sickle cell anemia	0		–		.11 ^b			
Down syndrome	0		–		.19 ^b			
Other genetic syndrome	0		–		.57 ^b			
Migraine	2	(7.7)	6.83	(0.59–78.6)	.12			
Prothrombotic state	0		–		1.00 ^b			
Oral contraceptives (females only)	0		–		1.00 ^b			
Indwelling catheter	0		–		1.00 ^b			
Iron deficiency anemia	1	(3.8)	1.07	(0.11–10.7)	.96			
Connective tissue disease	0		–		1.00 ^b			
Ventriculoperitoneal shunt	0		–		1.00 ^b			
Acute systemic illness								
Infection reported in prior week	2	(7.7)	0.49	(0.10–2.36)	.38			
Systemic sepsis or bacteremia	0		–		.33 ^b			
Meningitis	0		–		.06 ^b			
Dehydration	0		–		.34 ^b			
Head trauma	10	(38.5)	51.3	(6.13–428.8)	<.0001 ^a	162	(10.7–3435)	<.0001
Infarct characteristics at baseline								
Location								
Vascular distribution of infarction								
Anterior circulation	11	(42.3)	0.05	(0.01–0.15)	<.0001			
ACA	2	(7.7)	0.45	(0.09–2.13)	.31			
Lenticulostriate artery	9	(34.6)	0.60	(0.24–1.49)	.27			
Superficial MCA	10	(38.5)	0.20	(0.08–0.51)	.001			
Anterior choroidal artery	1	(3.8)	0.62	(0.07–5.60)	.67			
Posterior circulation	12	(46.2)	34.7	(7–172)	<.0001			
Basilar	3	(11.5)	–		.01 ^b			
SCA	7	(26.9)	30.2	(3.51–260)	.002			
AICA	1	(3.8)	–		.24 ^b			
PICA	9	(34.6)	21.4	(4.25–108)	<.0001			
PCA	6	(23.1)	2.81	(0.87–9.04)	.08			
Other location	0		–		.34 ^b			
Infarct side								
Unilateral	19	(73.1)	Reference					
Bilateral	7	(26.9)	1.24	(0.45–3.40)	.67			
Largest infarct volume (median) (IQR) (cm ³)	25.8	(3.9–95.4)						
Volume <25 cm ³	13	(50.0)	0.84	(0.35–2.04)	.71			

Continued on next page

On-line Table 6: Continued

Characteristic	Prevalence (n = 26)		Univariate Analyses			Multivariable Analysis ^a		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Vascular imaging findings								
Pathologic finding								
Occlusion	21	(80.8)	3.38	(1.16–9.82)	.03			
Stenosis	14	(53.8)	0.45	(0.18–1.11)	.08			
Irregularity	12	(46.2)	0.72	(0.30–1.75)	.47			
Ectasia or fusiform aneurysm or pseudoaneurysm	3	(11.5)	2.03	(0.45–9.17)	.36			
Banding	1	(3.8)	0.51	(0.06–4.47)	.55			
Intimal flap or mural hematoma	3	(11.5)	–		.01 ^b			
Pathologically affected vessels								
Vascular territories affected								
>1	4	(15.4)	Reference					
1	22	(84.6)	6.51	(2.06–20.6)	.001			
Side affected								
Bilateral	4	(15.4)	Reference					
Unilateral	22	(84.6)	6.51	(2.06–20.6)	.001			
Segment affected								
Supraclinoid ICA	9	(34.6)	0.22	(0.08–0.55)	.001			
Proximal MCA (M1)	10	(38.5)	0.06	(0.02–0.17)	<.0001			
Vertebrobasilar artery	16	(61.5)	7.89	(2.97–20.9)	<.0001			
Cervical arteries	18	(69.2)	18.5	(6.27–54.6)	<.0001 ^a	29.3	(5.43–159)	<.0001

Note:— indicates that cannot be calculated; ACA, anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery; CHD, congenital heart disease; AHD, acquired heart disease.

^a Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

^b P value was calculated with the Fisher exact test.

On-line Table 7: FCA-i—prevalence and univariate analyses of demographics and clinical and imaging characteristics of patients with FCA-i (n = 25) versus all other definite arteriopathy subgroups (n = 84)

Characteristic	Prevalence (n = 25)		Univariate Analyses			Multivariable Analysis ^a		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics								
Age by category								
0–3 yr	2	(8.0)	Reference					
4–7 yr	7	(28.0)	3.27	(0.63–17.1)	.16			
8–11 yr	6	(24.0)	7.64	(1.33–43.8)	.02			
12–15 yr	8	(32.0)	18.7	(3.14–111)	.001			
16–18 yr	2	(8.0)	3.11	(0.38–25.4)	.29			
Male sex	12	(48.0)	0.76	(0.31–1.87)	.55			
Race								
White	16	(64.0)	Reference					
Black	2	(8.0)	0.51	(0.10–2.53)	.41			
Indian/South Asian	2	(8.0)	0.51	(0.10–2.53)	.41			
East Asian	1	(4.0)	1.53	(0.13–18.00)	.74			
Middle Eastern	0		–					
First Nations/Aboriginal	1	(4.0)	–					
Mixed or other	2	(8.0)	0.88	(0.16–4.65)	.88			
Unknown	1	(4.0)	1.53	(0.13–18.0)	.74			
Stroke presentation								
Focal signs								
Hemiparesis	24	(96.0)	5.37	(0.67–42.9)	.11	8.34	(1.50–46.3)	.02
Dysarthria	13	(52.0)	3.68	(1.36–9.96)	.01 ^a			
Aphasia	8	(32.0)	4.19	(1.00–17.6)	.05			
Ataxia	7	(28.0)	1.40	(0.49–4.01)	.53			
Visual field deficit	2	(8.0)	0.60	(0.12–3.02)	.54			
Nonfocal signs								
Headache	16	(64.0)	3.19	(1.22–8.30)	.02			
Decreased level of consciousness	4	(16.0)	0.43	(0.13–1.39)	.16			
Nausea/vomiting	3	(12.0)	0.28	(0.08–1.04)	.06			
Seizures at presentation	4	(16.0)	0.49	(0.15–1.58)	.23			
Vertigo	2	(8.0)	0.55	(0.11–2.76)	.47			
Diplopia	0		–		1.00 ^b			
Risk factors or comorbidities (not mutually exclusive)								
Cardiac disease (CHD-AHD or both)	0				.33 ^b			
Congenital heart disease	0		–					
Acquired heart disease	0							
Other chronic disorders								
Sickle cell anemia	0		–		.12 ^b			
Down syndrome	0		–		.35 ^b			
Other genetic syndrome	0		–		.57 ^b			
Migraine	1	(4.0)	1.71	(0.15–19.7)	.67			
Prothrombotic state	0		–		1.00 ^b			
Indwelling catheter	0		–		1.00 ^b			
Iron deficiency anemia	0		–		.57 ^b			
Connective tissue disease	0		–		1.00 ^b			
Ventriculoperitoneal shunt	0		–		1.00 ^b			
Acute systemic illness								
Infection reported in prior week	3	(12.0)	0.90	(0.23–3.54)	.89			
Systemic sepsis or bacteremia	0		–		.33 ^b			
Meningitis	0		–		.07 ^b			
Dehydration	0		–		.59 ^b			
Head trauma	0		–		.07 ^b			
Infarct characteristics at baseline								
Location								
Vascular distribution of infarction								
Anterior circulation	25	(100.0)	–		.006 ^b			
ACA	0		–		.02 ^b			
Lenticulostriate artery	19	(76.0)	6.01	(2.16–16.7)	.001 ^a	45.6	(4.81–433)	.001
Superficial MCA	14	(56.0)	0.54	(0.22–1.35)	.19			
Anterior choroidal artery	4	(16.0)	7.81	(1.34–45.6)	.02			
Posterior circulation	0		–		.04 ^b			
Basilar	0		–		1.00 ^b			
SCA	0		–		.19 ^b			
AICA	0		–		1.00 ^b			
PICA	0		–		.07 ^b			
PCA	0		–		.04 ^b			
Other location	0		–		.59 ^b			
Infarct side					.001 ^b			
Unilateral	25	(100.0)						
Bilateral	0							
Largest infarct volume (median) (IQR) (cm ³)	13.8	(3.3–20.1)						
Volume <25 cm ³	20	(80.0)	6.84	(2.33–20.0)	<.0001 ^a	5.48	(1.31–23.0)	.02

Continued on next page

On-line Table 7: Continued

Characteristic	Prevalence (n = 25)		Univariate Analyses			Multivariable Analysis ^a		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Vascular imaging findings								
Pathologic finding								
Occlusion	10	(40.0)	0.32	(0.13–0.79)	.01			
Stenosis	15	(60.0)	0.64	(0.25–1.61)	.34			
Irregularity	15	(60.0)	1.5	(0.61–3.72)	.38			
Ectasia or fusiform aneurysm or pseudoaneurysm	0		–		.19 ^b			
Banding	6	(24.0)	26.2	(2.98–230)	.003 ^a	193	(1.72–22K)	.03
Intimal flap or mural hematoma	0		–		1.00 ^b			
Pathologically affected vessels								
Arterial segments affected								
>1	18	(72.0)	Reference					
1	7	(28.0)	3.69	(1.19–11.5)	.02 ^a	18.9	(1.49–240)	.02
Vascular territories affected								
>1	0				<.0001 ^b			
1	25	(100.0)	–					
Side affected								
Bilateral	0		–		<.0001 ^b			
Unilateral	25	(100.0)	–					
Segment affected								
Supraclinoid ICA	10	(40.0)	0.3	(0.12–0.75)	.01			
Proximal MCA (M1)	24	(96.0)	8.52	(1.09–66.7)	.04 ^a	24.2	(1.45–405)	.03
Vertebrobasilar	0		–					
Cervical arteries	1	(4.0)	0.09	(0.01–0.72)	.02			

Note:—K indicates thousands; –, cannot be calculated; ACA, anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery; CHD, congenital heart disease; AHD, acquired heart disease; IQR, interquartile range.

^a Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

^b P value was calculated with the Fisher exact test.

On-line Table 8: Demographics and clinical characteristics of patients with FCA-d and FCA-i

	FCA-i (TCA)		FCA-d (Dissection)		Logistic Regression		
	No.	%	No.	%	OR	95% CI	P Value
Demographics							
Age (median) (IQR) (yr)	11.3	(6.9–15.9)	14.5	(6.9–15.9)	1.06	(0.87–1.29)	.55
Age by category							
0–3 yr	2	(8.0)	1	(14.3)	Reference		
4–7 yr	7	(28.0)	1	(14.3)	0.29	(0.01–6.91)	.44
8–11 yr	6	(24.0)	1	(14.3)	0.33	(0.01–8.18)	.50
12–15 yr	8	(32.0)	3	(42.9)	0.75	(0.05–11.6)	.84
16–18 yr	2	(8.0)	1	(14.3)	1.00	(0.03–29.8)	1.00
Male sex	12	(48.0)	3	(42.9)	0.81	(0.15–4.40)	.81
Race							
White	16	(64.0)	6	(85.7)	3.38 ^a	(0.35–32.6)	.29
Black	2	(8.0)	0	(0.0)			
Indian/South Asian	2	(8.0)	0	(0.0)			
East Asian	1	(4.0)	0	(0.0)			
First Nations/Aboriginal	1	(4.0)	0	(0.0)			
Mixed or other	2	(8.0)	1	(14.3)			
Unknown	1	(4.0)	0	(0.0)			
Ethnicity							
Hispanic	1	(4.0)	0	(0.0)			.54 ^b
Non-Hispanic	23	(92.0)	6	(85.7)			
Mixed or other	1	(4.0)	1	(14.3)			
Country							
United States	13	(52.0)	5	(71.4)	2.31 ^c	(0.37–14.2)	.37
Canada	7	(28.0)	1	(14.3)			
Australia	5	(20.0)	1	(14.3)			
Stroke presentation							
Focal signs							
Hemiparesis	24	(96.0)	7	(100.0)			1.00 ^b
Dysarthria	13	(52.0)	2	(28.6)	0.34	(0.05–2.31)	.27
Aphasia	8	(32.0)	2	(28.6)	0.25	(0.03–2.32)	.22
Ataxia	7	(28.0)	3	(42.9)	2.14	(0.34–13.4)	.42
Visual field deficit	2	(8.0)	1	(14.3)	1.67	(0.13–21.7)	.70
Nonfocal signs							
Headache	16	(64.0)	5	(71.4)	1.41	(0.23–8.78)	.72
Decreased level of consciousness	4	(16.0)	2	(28.6)	1.90	(0.27–13.5)	.52
Nausea/vomiting	3	(12.0)	1	(14.3)	1.47	(0.12–17.2)	.76
Seizures at presentation	4	(16.0)	1	(14.3)	0.88	(0.08–9.38)	.91
Vertigo	2	(8.0)	0	(0.0)			1.00 ^b
Diplopia	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Papilledema	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Risk factors or comorbidities (not mutually exclusive)							
Cardiac disease							
Congenital heart disease	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Acquired heart disease	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Isolated patent foramen ovale	3	(12.0)	0	(0.0)			1.00 ^b
Other chronic disorders							
Sickle cell anemia	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Down syndrome	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Other genetic syndrome	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Migraine	1	(4.0)	0	(0.0)			1.00 ^b
Prothrombotic state	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Oral contraceptives (females only)	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Indwelling catheter	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Iron deficiency anemia	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Aneurysm	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Connective tissue disease	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Ventriculoperitoneal shunt	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Acute systemic illness							
Fever lasting >48 hr	1	(4.0)	0	(0.0)			1.00 ^b
Systemic sepsis or bacteremia	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Meningitis	NA: none in FCA-i group		NA: none in FCA-d group		NA		

Continued on next page

On-line Table 8: Continued

	FCA-i (TCA)		FCA-d (Dissection)		Logistic Regression		
	No.	%	No.	%	OR	95% CI	P Value
Major infection (either of above)	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Dehydration	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Shock	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Viral gastroenteritis	NA: none in FCA-i group		NA: none in FCA-d group		NA		
Head trauma	0	(0.0)	5	(71.4)	<.0001 ^b		

Note:—NA indicates not applicable.

^a Testing white vs other.

^b Fisher exact test.

^c Testing United States vs other.

On-line Table 9: Imaging characteristics of patients with FCA-d and FCA-i

	FCA-i (TCA)		FCA-d (Dissection)		Logistic Regression		
	No.	%	No.	%	OR	95% CI	P Value
Infarct characteristics at baseline							
Location							
Vascular distribution of infarction							
Anterior circulation							
All FAC-i group anterior							
All FAC-d group anterior							
NA							
ACA							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Lenticulostriate artery							
19 (76.0)							
5 (71.4)							
0.81 (0.12–5.17)							
.81							
Superficial MCA							
14 (56.0)							
6 (85.7)							
4.71 (0.49–45.2)							
.18							
Anterior choroidal artery							
4 (16.0)							
1 (14.3)							
0.88 (0.08–9.38)							
.91							
Posterior circulation							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Basilar artery							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
SCA							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
AICA							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
PICA							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
PCA							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Other							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Infarct side							
Left side							
14 (56.0)							
2 (28.6)							
Reference							
Right side							
11 (44.0)							
5 (71.4)							
3.18 (0.52–19.6)							
.21							
Bilateral							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Volume of largest infarct (cm ³)							
13.8 (3.3–20.1)							
87.6 (8.6–97.9)							
1.02 (0.999–1.03)							
.05							
Hemorrhagic transformation							
3 (12.0)							
2 (28.6)							
3.5 (0.44–28.1)							
.24							
Vascular imaging findings							
Pathologic finding							
Occlusion							
10 (40.0)							
6 (85.7)							
9.00 (0.94–86.5)							
.06							
Stenosis							
15 (60.0)							
6 (85.7)							
4.00 (0.42–38.5)							
.23							
Irregularity							
15 (60.0)							
4 (57.1)							
0.89 (0.16–4.85)							
.89							
Ectasia or fusiform aneurysm or pseudoaneurysm							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Banding							
6 (24.0)							
0 (0.0)							
Intimal flap or mural hematoma							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Pathologically affected vessels							
Arterial segments affected							
≤1							
7 (28.0)							
0 (0.0)							
.30 ^a							
>1							
18 (72.0)							
7 (100.0)							
Vascular territories affected							
1							
25 (100.0)							
7 (100.0)							
NA							
>1							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Side affected							
Unilateral							
25 (100.0)							
7 (100.0)							
NA							
Bilateral							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Segment affected							
Supraclinoid ICA							
10 (40.0)							
7 (100.0)							
.008 ^a							
Proximal MCA (M1)							
24 (96.0)							
7 (100.0)							
1.00 ^a							
Vertebrobasilar							
NA: none in FAC-i group							
NA: none in FAC-d group							
NA							
Cervical arteries							
1 (4.0)							
4 (57.1)							
32 (2.63–389)							
.007							

Note:—ACA indicates anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery; NA, not applicable.

^a Fisher exact test.

On-line Table 10: Moyamoya—prevalence and univariate analyses of demographics and clinical and imaging characteristics for patients with Moyamoya (n = 34) versus all other definite arteriopathy subgroups (n = 75)

Characteristic	Prevalence (n = 34)		Univariate Analyses			Multivariable Analysis ^a		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Demographics								
Age by category								
0–3 yr	10	(29.4)	Ref					
4–7 yr	14	(41.2)	1.22	(0.44–3.34)	.70			
8–11 yr	5	(14.7)	0.83	(0.23–3.03)	.78			
12–15 yr	3	(8.8)	0.55	(0.12–2.41)	.42			
16–18 yr	2	(5.9)	0.44	(0.08–2.46)	.35			
Male sex	17	(50.0)	0.83	(0.37–1.87)	.65			
Race								
White	16	(47.1)	Ref					
Black	10	(29.4)	7.65	(2.11–27.8)	.002 ^a	43.2	(2.38–781)	.01
Indian/South Asian	2	(5.9)	0.51	(0.10–2.53)	.41			
East Asian	1	(2.9)	1.53	(0.13–18.0)	.74			
Middle Eastern	0		–					
First Nations/Aboriginal	0		–					
Mixed or other	3	(8.8)	1.53	(0.34–6.84)	.58			
Unknown	2	(5.9)	6.13	(0.52–72.1)	.15			
Stroke presentation								
Focal signs								
Hemiparesis	29	(85.3)	1.22	(0.40–3.73)	.73			
Dysarthria	8	(23.5)	0.62	(0.24–1.55)	.30			
Aphasia	11	(32.4)	1.51	(0.62–3.70)	.36			
Ataxia	5	(14.7)	0.51	(0.17–1.50)	.22			
Visual field deficit	3	(8.8)	0.81	(0.20–3.27)	.77			
Nonfocal signs								
Headache	3	(8.8)	0.08	(0.02–0.30)	<.0001			
Decreased level of consciousness	4	(11.8)	0.27	(0.09–0.87)	.03 ^a	0.01	(0.0009–0.19)	.002
Nausea/vomiting	8	(23.5)	0.83	(0.32–2.16)	.71			
Seizures at presentation	12	(35.3)	2.1	(0.85–5.21)	.11			
Vertigo	0		–		.01 ^b			
Diplopia	0		–		1.00 ^b			
Risk factors or comorbidities (not mutually exclusive)								
Cardiac disease (CHD and/or AHD)								
Cardiac disease (CHD and/or AHD)	3	(8.8)	2.32	(0.44–12.2)	.32			
Congenital heart disease	3	(8.8)						
Acquired heart disease	0							
Other chronic disorders								
Sickle cell anemia	9	(26.5)	–		<.0001 ^b			
Down syndrome	6	(17.6)	15.9	(1.83–138)	.01 ^a	2099	(134–328K)	.003
Other genetic syndrome	0		–		.31 ^b			
Migraine	0		–		.55 ^b			
Prothrombotic state		(2.9)	2.24	(0.14–36.9)	.57			
Indwelling catheter	0		–		1.00 ^b			
Iron deficiency anemia	2	(5.9)	2.28	(0.31–16.9)	.42			
Connective tissue disease	0		–		1.00 ^b			
Ventriculoperitoneal shunt	0		–		1.00 ^b			
Acute systemic illness								
Infection reported in prior 7 days								
Infection reported in prior 7 days	8	(23.5)	3.54	(1.12–11.2)	.03 ^a	30.0	(1.58–569)	.02
Systemic sepsis or bacteremia	0		–		.17 ^b			
Meningitis	0		–		.02 ^b			
Dehydration	4	(11.8)	9.87	(1.06–91.9)	.04			
Head trauma	1	(2.9)	0.20	(0.02–1.61)	.13			
Infarct characteristics at baseline								
Location								
Vascular distribution of infarction								
Anterior circulation								
Anterior circulation	31	(91.2)	3.03	(0.82–11.1)	.10			
ACA	5	(14.7)	1.12	(0.35–3.57)	.85			
Lenticulostriate artery	8	(23.5)	0.27	(0.11–0.67)	.005			
Superficial MCA	30	(88.2)	5.58	(1.79–17.4)	.003 ^a			
Anterior choroidal artery	0		–		.17 ^b			
Posterior circulation								
Posterior circulation	0		–		.005 ^b			
Basilar artery	0		–		.55 ^b			
SCA	0		–		.06 ^b			
AICA	0		–		1.00 ^b			
PICA	0		–		.02 ^b			
PCA	0		–		.005 ^b			
Other location	4	(11.8)	9.87	(1.06–91.9)	.04			
Infarct side								
Unilateral	24	(70.6)	Ref					
Bilateral	10	(29.4)	1.54	(0.61–3.86)	.36			
Largest infarct volume (median) (IQR) (cm ³)	54.6	(4.39–88.9)						
Volume ≥25 cm ³	22	(64.7)	1.99	(0.86–4.86)	.11			

Continued on next page

On-line Table 10: Continued

Characteristic	Prevalence (n = 34)		Univariate Analyses			Multivariable Analysis ^a		
	No.	%	OR	95% CI	P Value	OR	95% CI	P Value
Vascular imaging findings								
Pathologic finding								
Occlusion	25	(73.5)	2.18	(0.90–5.30)	.09			
Stenosis	26	(76.5)	1.83	(0.73–4.60)	.20			
Irregularity	14	(41.2)	0.52	(0.23–1.19)	.12			
Ectasia or fusiform aneurysm or pseudoaneurysm	1	(2.9)	0.29	(0.03–2.50)	.26			
Banding	0		–		.10 ^b			
Intimal flap or mural hematoma	0		–		.55 ^b			
Vascular territories affected								
>1	31	(91.2)	32.7	(8.93–120)	<.0001 ^a	325.0	(19.1–5522)	<.0001
1	3	(8.8)	Ref					
Segment affected								
Supraclinoid ICA	32	(94.1)	17.3	(3.87–77.6)	<.0001 ^a	61.0	(2.32–1602)	.01
Proximal MCA (M1)	32	(94.1)	6.22	(1.37–28.3)	.02			
Vertebrobasilar artery	7	(20.6)	0.59	(0.22–1.54)	.28			
Cervical arteries	6	(17.6)	0.55	(0.20–1.52)	.25			

Note:—Ref indicates reference; –, cannot be calculated; ACA, anterior cerebral artery; SCA, superior cerebellar artery; PCA, posterior cerebral artery; CHD, congenital heart disease; AHD, acquired heart disease; IQR, interquartile range.

^a Remains significant ($P < .05$) in the multivariable model after stepwise regression ($P < .05$).

^b P value was calculated with the Fisher exact test.

On-line Table 11: Multivariable analyses with odds ratios (95% confidence intervals) and P values for cardioembolism and arteriopathy subtypes

Arteriopathy Subtype	Cardioembolic	Dissection	FCA-i	Moyamoya	Vasculitis	Other Definite
Demographic characteristics						
Black vs other				17 (1.77–163) $P = .01$ (10 patients of 34)		
Clinical characteristics						
Congenital or acquired heart disease	991 (99–11K) $P < .0001$ (63 patients of 65)					
Down syndrome				312 (8.02–12K) $P = .002$ (6 patients of 34)	11 Patients of 15 had meningitis; none in other dx groups 2456 (27–222K) $P < .001$ (5 patients of 15)	
Meningitis						
Sepsis/bacteremia						
Head trauma		162 (10.7–3435) $P < .0001$ (10 patients of 26)				
Presentation						
Dysarthria			8.03 (1.36–47.3) $P = .02$ (13 patients of 25)			
Nausea/vomiting		4.89 (1.03–23.3) $P = .05$ (3 patients of 24)				
Vertigo		37.7 (4.2–338) $P = .001$ (8 patients of 26)				
Decreased level of consciousness						
Infarct characteristics at baseline: location						
Lenticulostriate artery			55.8 (5.78–539) $P = .001$ (19 patients of 25)	0.03 (0.003–0.22) $P = .001$ (4 patients of 34)	42.7 (2.98–613) $P = .006$ (11 patients of 15)	
Infarct characteristics at baseline: volume						
Infarct volume			0.98 (0.97–0.99) $P = .05$ (median, 13.8; IQR, 3.3–13.8)			
Vascular imaging abnormal findings						
Occlusion						
Stenosis	0.12 (0.02–0.81) $P < .03$ (7 patients of 65)					
Irregularity	0.04 (0.004–0.42) $P = .007$ (6 patients of 65)					
Banding						
Vascular territories affected						
>1			293 (2.29–37K) $P = .02$ (6 patients of 25)	131 (14–1168) $P < .0001$ (31 patients of 34)		
Arterial segments affected						
>1			0.05 (0.004–0.67) $P = .02$ (18 patients of 25)			
Affected artery						
Proximal MCA (M1)			25.4 (1.52–424) $P = .02$ (24 patients of 25)			
Distal ICA (supracallosal artery)						
Cervical artery		29.3 (5.43–159) $P < .0001$ (18 patients of 26)		22 (1.99–237) $P = .01$ (32 patients of 34)		25.8 (1.22–547.4) 0.04 (8 patients of 9)

Note:—dx indicates diagnosis; K, thousands; IQR, interquartile range.